Drugs / interferon alfa
interferon alfa
also known as
IFN · IFN-α · interferon-alpha · INTERFERON-ALPHA-n1 · recombinant interferon alfa · WELLFERON · alpha interferon · IFN alfa · +4 more
Trials 33
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01220648 | Apr 2012 → Jan 2014 | chronic myeloid leukemia | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT00095862 | Nov 2004 → ? | breast cancer | Wiseman Research Initiatives LLC | Terminated | No outcome recorded |
| Phase 1/2 | NCT00004063 | Aug 1999 → Nov 2011 | cancer of unknown primary site | The University of Texas Health Science Center, Houston | Unknown | No outcome recorded |
| Phase 1/2 | NCT00005615 | Jul 1997 → Dec 2005 | cutaneous melanoma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 217 trials | ||||||
| Phase 2 | NCT07671495 | Jan 2014 → Dec 2017 | cutaneous melanoma | MIPO Clinic | Completed | No outcome recorded |
| Phase 2 | NCT01834963 | Mar 2013 → Feb 2018 | hepatocellular carcinoma | Kansai Hepatobiliary Oncology Group | Unknown | No outcome recorded |
| Phase 2 | NCT00363649 | Sep 2006 → Sep 2017 | leukemia | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 2 | NCT00098618 | Oct 2004 → Jan 2006 | clear cell renal carcinoma, papillary renal cell carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2 | NCT00082862 | Jul 2002 → Nov 2012 | malignant pancreatic neoplasm | The University of Texas Health Science Center, Houston | Unknown | No outcome recorded |
| Phase 2 | NCT00005847 | Apr 2001 → Jul 2004 | prostate cancer | Eastern Cooperative Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00005987 | Aug 2000 → Jul 2003 | plasma cell myeloma | Masonic Cancer Center, University of Minnesota | Terminated | No outcome recorded |
| Phase 2 | NCT00005984 | Aug 2000 → Sep 2005 | leukemia | Masonic Cancer Center, University of Minnesota | Terminated | No outcome recorded |
| Phase 2 | NCT00004903 | Oct 1999 → ? | plasma cell myeloma | Robert H. Lurie Cancer Center | Unknown | No outcome recorded |
| Phase 2 | NCT00004231 | Oct 1999 → Aug 2006 | lymphoma | Northwestern University | Completed | No outcome recorded |
| Phase 2 | NCT00004088 | Apr 1999 → Jan 2018 | plasma cell myeloma | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00004039 | Jun 1998 → Jan 2000 | lymphoma | Hoag Memorial Hospital Presbyterian | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00002847 | Sep 1995 → ? | kidney cancer | Blumenthal Cancer Center at Carolinas Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT00002669 | Jun 1995 → Aug 2002 | cutaneous melanoma | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 2 | NCT00002598 | Jun 1994 → Jun 2004 | leukemia | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00002504 | Aug 1992 → Feb 1998 | leukemia, myelodysplastic syndrome, myeloproliferative neoplasm, plasma cell neoplasm +1 | Hoag Memorial Hospital Presbyterian | Completed | No outcome recorded |
| Phase 2 | NCT00002470 | Sep 1990 → Jan 2004 | carcinoid tumor, lung cancer | Mid-Atlantic Oncology Program | Completed | No outcome recorded |
| Phase 312 trials · 1 met primary · 1 missed | ||||||
| Phase 3 | NCT04534725 | Dec 2020 → Nov 2022 | COVID-19, cancer, viral respiratory tract infection | Peter MacCallum Cancer Centre, Australia | Completed | Mixed |
| Phase 3 | NCT00072046 | Oct 2003 → Jan 2004 | kidney cancer | Alliance for Clinical Trials in Oncology | Completed | Missed primary |
| Phase 3 | NCT00065468 | Jul 2003 → Jun 2006 | renal cell carcinoma | Pfizer | Completed | Mixed |
| Phase 3 | NCT00055874 | Jun 2002 → Mar 2012 | leukemia | Heidelberg University | Completed | Met primary |
| Phase 3 | NCT00006237 | Aug 2000 → Jul 2012 | cutaneous melanoma | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 3 | NCT00291369 | Dec 1999 → Feb 2005 | renal cell carcinoma | Centre Leon Berard | Completed | No outcome recorded |
| Phase 3 | NCT00002868 | Nov 1997 → Mar 2004 | leukemia | Eastern Cooperative Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00003152 | Mar 1997 → Nov 1999 | lymphoma | European Organisation for Research and Treatment of Cancer - EORTC | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00002869 | Apr 1995 → ? | leukemia | Medical Research Council | Unknown | No outcome recorded |
| Phase 3 | NCT00002771 | Jan 1995 → ? | leukemia | German CML Study Group | Unknown | No outcome recorded |
| Phase 3 | NCT00004804 | Aug 1993 → ? | chronic hepatitis C virus infection | National Center for Research Resources (NCRR) | Completed | No outcome recorded |
| Phase 3 | NCT00003063 | Nov 1991 → ? | colorectal cancer | European Institute of Oncology | Unknown | No outcome recorded |
| Comparator or background therapy6 trials | ||||||
| Phase 2 | NCT00110058 Background | Feb 2005 → Jul 2006 | leukemia | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00003727 Background | Mar 1999 → Mar 2005 | leukemia | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 3 | NCT06079879 Comparator | Dec 2023 → Jul 2027 expected | essential thrombocythemia | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT01094964 Background | Oct 2009 → Oct 2013 | urinary bladder cancer | Cancer Research Campaign Clinical Trials Centre | Unknown | Missed primary |
| Phase 3 | NCT00631371 Comparator | Apr 2008 → Apr 2012 | renal cell carcinoma | Pfizer | Completed | Missed primary |
| Phase 3 | NCT00083889 Comparator | Aug 2004 → Sep 2008 | renal cell carcinoma | Pfizer | Completed | Met primary |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2012-03-06 | Merck Sharp & Dohme LLC | Results Results from Investigational Studies with VICTRELIS™ (boceprevir) Presented at the Conference on Retroviruses and Opportunistic Infections to Understand Potential Use in Patients Coinfected with Chronic Hepatitis C and HIV-1 merck.com ↗
In the study, a higher percentage of patients receiving VICTRELIS in combination with peginterferon alfa-2b and ribavirin had undetectable hepatitis C virus (HCV-RNA) 12 weeks after treatment ended (sustained virologic response-12 1 or SVR-12) than patients receiving peginterferon alfa-2b and ribavirin alone. |
| 2011-11-05 | Vertex Pharmaceuticals Incorporated | Results Positive Interim Data From a Phase 2 Study of INCIVEK™ (telaprevir) Combination Therapy in People Co-Infected with Hepatitis C and HIV Presented at The Liver Meeting® vrtx.com ↗
Data showed 74 percent (28/38) of patients who were treated with INCIVEK (in-SEE-veck) combination therapy had undetectable hepatitis C virus (HCV RNA) at Week 24 of treatment compared to 55 percent (12/22) who were treated with pegylated-interferon and ribavirin alone. |
| 2011-09-14 | Vertex Pharmaceuticals Incorporated | Results New England Journal of Medicine Publishes Data from Phase 3 ILLUMINATE Study of INCIVEK™ (telaprevir) in Hepatitis C vrtx.com ↗
In this study, 65 percent (352/540) of people had undetectable hepatitis C virus at weeks 4 and 12. |
| 2006-05-21 | Vertex Pharmaceuticals Incorporated | Results Researchers Report Results for 28-day Phase II Study of VX-950 in Combination with Pegylated Interferon and Ribavirin in Hepatitis C Patients vrtx.com ↗
Researchers reported for the first time today that 11 of these patients (92%) continue to have no detectable virus in their blood at the end of 12 additional weeks of follow-on peg-IFN+RBV dosing. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2012-03-06 | Merck Sharp & Dohme LLC | Results from Investigational Studies with VICTRELIS™ (boceprevir) Presented at the Conference on Retroviruses and Opportunistic Infections to Understand Potential Use in Patients Coinfected with Chronic Hepatitis C and HIV-1 merck.com ↗ |
| 2011-11-05 | Vertex Pharmaceuticals Incorporated | Positive Interim Data From a Phase 2 Study of INCIVEK™ (telaprevir) Combination Therapy in People Co-Infected with Hepatitis C and HIV Presented at The Liver Meeting® vrtx.com ↗ |
| 2011-09-14 | Vertex Pharmaceuticals Incorporated | New England Journal of Medicine Publishes Data from Phase 3 ILLUMINATE Study of INCIVEK™ (telaprevir) in Hepatitis C vrtx.com ↗ |
| 2006-05-21 | Vertex Pharmaceuticals Incorporated | Researchers Report Results for 28-day Phase II Study of VX-950 in Combination with Pegylated Interferon and Ribavirin in Hepatitis C Patients vrtx.com ↗ |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 46 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | interferon-alfa | “temsirolimus plus bevacizumab versus interferon alfa (IFN) plus bevacizumab in metastatic renal cell carcinoma (mRCC).” PMID 24297945 ↗ Dec 201340“The optimal dose of interferon-alfa (IFN) for chronic myeloid leukemia (CML) is unknown.” PMID 15010373 ↗ Mar 2004 |
| Known as | alpha interferon | “two cytokine treatments, Interleukin-2 (IL2) and/or alpha interferon (IFN), for patients with intermediate chance of response in metastatic renal cell carcinoma.” NCT00291369 ↗ |
| Known as | IFN | “two cytokine treatments, Interleukin-2 (IL2) and/or alpha interferon (IFN), for patients with intermediate chance of response in metastatic renal cell carcinoma.” NCT00291369 ↗3“temsirolimus plus bevacizumab versus interferon alfa (IFN) plus bevacizumab in metastatic renal cell carcinoma (mRCC).” PMID 24297945 ↗ Dec 2013 “The optimal dose of interferon-alfa (IFN) for chronic myeloid leukemia (CML) is unknown.” PMID 15010373 ↗ Mar 2004 “Interferon alfa (IFN-alpha) is the historic standard initial treatment for RCC.” PMID 20368558 ↗ Apr 2010 |
| Known as | IFN alfa | “6 MU of IFN alfa (Roferon) given Sub Cutaneously three time /week” NCT00065468 ↗ |
| Known as | IFN-A | “interferon alfa (IFN-A) subcutaneously (SC) daily beginning after WBC reduction” NCT00002771 ↗ |
| Known as | IFN-alpha | “Interferon alfa (IFN-alpha) is the historic standard initial treatment for RCC.” PMID 20368558 ↗ Apr 2010 |
| Known as | IFN-α | “a daily nasal spray of interferon-alpha (IFN-α) would reduce the incidence of COVID-19 or community-acquired respiratory viral infections in adult cancer patients.” PMID 40874769 ↗ Feb 20262“CALGB 90206 was a phase III trial of 732 patients with metastatic renal cell carcinoma (mRCC) comparing bevacizumab plus IFNα (BEV + IFN) with IFNα alone (IFN).” PMID 34965953 ↗ Jul 2022 “imatinib 400 mg/d plus interferon alfa (IFN-α; n = 351)” PMID 21422420 ↗ Mar 2011 |
| Known as | Interferon Alfa ; IFN、 | “Interferon Alfa ; IFN、” NCT01834963 ↗ |
| Known as | interferon-alpha | “a daily nasal spray of interferon-alpha (IFN-α) would reduce the incidence of COVID-19 or community-acquired respiratory viral infections in adult cancer patients.” PMID 40874769 ↗ Feb 20262“Hepatic Arterial Infusion of 5-fluorouracil combined with systemic administration of Interferon-alpha” NCT01834963 ↗ “Interferon-alpha (IFN-alpha) is a standard initial cytokine therapy in RCC” PMID 15102658 ↗ Apr 2004 |
| Known as | INTERFERON-ALPHA-n1 | “INTERFERON-ALPHA-n1 (WELLFERON)” NCT00002869 ↗1“INTERFERON-ALPHA-n1 (WELLFERON)” NCT00002868 ↗ |
| Known as | recombinant interferon alfa | “Biological: recombinant interferon alfa” NCT00072046 ↗1“Biological: recombinant interferon alfa” NCT00098618 ↗ |
| Known as | Roferon | “Interferon alfa (Roferon) 3 MU given Sub Cutaneously three time /week for the first week, 9 MU given Sub Cutaneously three time /week for the second week, 18 MU given Sub...” NCT00065468 ↗ |
| Known as | WELLFERON | “INTERFERON-ALPHA-n1 (WELLFERON)” NCT00002869 ↗1“INTERFERON-ALPHA-n1 (WELLFERON)” NCT00002868 ↗ |
| Modality | Protein / enzyme biologic | “recombinant interferon alfa” NCT00002470 ↗ |
| Route | Subcutaneous | “interferon alfa subcutaneously 3 times a week for 12 weeks” NCT00002470 ↗ |